Portugal
Kannoli Pharma, a brand owned by Alkannoli L.D.A., is emerging as a key player in the burgeoning European medical cannabis industry. Positioned as a disruptor, Kannoli Pharma focuses on the production and manufacture of EU-GMP certified medical cannabis products tailored for the European market. Founded in 2020, the company is headquartered in Portugal and operates in the Manufacturing sector.
The company's strategic edge is evidenced by its commitment to environmental sustainability through its scalable production facility, which aims to produce high-quality and innovative medical cannabis products. These products serve as therapeutic agents for an array of medical conditions, including cancer, chronic pain, depression, and multiple sclerosis, among others.
Despite its recent establishment, Kannoli Pharma has not yet disclosed significant investment rounds or partnerships. For investors, the company presents an intriguing opportunity within a nascent market marked by rapid growth potential.
